FTC Dems want section 5 used on drug prices
A Federal Trade Commission report on the agency’s authority to limit price increases for off-patent drugs has drawn disagreement from two commissioners.
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10